Diabetes drug may protect hearts by reducing scarring
NCT ID NCT05367063
First seen Dec 16, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This study looked at whether canagliflozin, a diabetes medicine, can reduce scarring in the heart muscle of people with type 2 diabetes who are at high risk for heart problems. 45 participants took the drug, and researchers used MRI scans to measure changes in heart scarring. The goal was to understand how this drug might protect the heart.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.